AR028812A1 - Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades - Google Patents

Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades

Info

Publication number
AR028812A1
AR028812A1 ARP000100123A ARP000100123A AR028812A1 AR 028812 A1 AR028812 A1 AR 028812A1 AR P000100123 A ARP000100123 A AR P000100123A AR P000100123 A ARP000100123 A AR P000100123A AR 028812 A1 AR028812 A1 AR 028812A1
Authority
AR
Argentina
Prior art keywords
compounds
prepare
substituted
acyl
useful
Prior art date
Application number
ARP000100123A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR028812A1 publication Critical patent/AR028812A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se trata de compuestos de amida capaces de producir actividad colinérgica, y que son utiles para tratar desordenes del sistema nervioso central. Dichos compuestos tienen la formula general (1) en donde R1 es acilo, R2 es alquilo inferior, alcoxi inferior, alquilamino inferior, alquenilo inferior, alqueniloxi inferior, alquenilamino inferior, alquinilo inferior, alquiniloxi inferior, alquinilamino inferior, cicloalquilo (inferior), cicloalquiloxi (inferior), cicloalquilamino (inferior), arilo, ariloxi, arilamino, un grupo heterocíclico o amino sustituido con un grupo heterocíclico, cada uno de los cuales puede sustituirse con un sustituyente (s) adecuado; o acilo; A es un enlace simple, -CO- o -SO2-, E es un alquileno inferior opcionalmente sustituido con sustituyentes adecuado (s), X es CH o N, Y es un enlace simple, alquileno o -NR5- (en donde R5 es hidrogeno, alquilo inferior, alquilo inferior sustituido, un grupo N-protector, arilo, acilo o un grupo heterocíclico), Q es -CH2-., -CO -, SO2- o-N=CH-, y R3 y R4 son cada uno hidrogeno o alquilo inferior, o se toman juntos para formar alquileno inferior condensado opcionalmente con un hidrocarbono cíclico o un anillo heterocíclico siempre que cuando X es N, entonces 1) Y es un enlace simple y Q es -CH2-, -CO- o-SO2-, o 2) Y es alquileno inferior, y las sales del mismo farmacéuticamente aceptable. También se describen los procesos de la preparacion de los mismos y las composiciones farmacéuticas que los comprenden y el uso de dichos compuestos para la fabricacion de medicamentos.
ARP000100123A 1999-01-14 2000-01-12 Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades AR028812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds

Publications (1)

Publication Number Publication Date
AR028812A1 true AR028812A1 (es) 2003-05-28

Family

ID=3812385

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100123A AR028812A1 (es) 1999-01-14 2000-01-12 Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades

Country Status (21)

Country Link
US (2) US6710043B1 (es)
EP (1) EP1140836B1 (es)
JP (2) JP3617454B2 (es)
KR (2) KR100525809B1 (es)
CN (1) CN1142910C (es)
AR (1) AR028812A1 (es)
AT (1) ATE502923T1 (es)
AU (1) AUPP818099A0 (es)
BR (1) BRPI0008753B8 (es)
CA (1) CA2360360C (es)
CZ (1) CZ20012562A3 (es)
DE (1) DE60045759D1 (es)
ES (1) ES2363492T3 (es)
HK (1) HK1044337B (es)
HU (1) HU230422B1 (es)
IL (2) IL143841A0 (es)
RU (1) RU2208608C2 (es)
TR (1) TR200102038T2 (es)
TW (1) TWI229075B (es)
WO (1) WO2000042011A1 (es)
ZA (1) ZA200104713B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US20040029894A1 (en) * 2000-12-07 2004-02-12 Nobuya Matsuoka Nootropic effect enhancer
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
WO2004052102A1 (en) * 2002-12-06 2004-06-24 Dow Agrosciences Llc Synergistic compositions
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1814875A4 (en) 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE HYDROLASE EPOXYDE
US20080009477A1 (en) * 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2008051875A2 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Adamantylurea compounds as soluble epoxide hydrolase inhibitors
CA2666482A1 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2008133198A1 (ja) 2007-04-20 2008-11-06 Senju Pharmaceutical Co., Ltd. 神経突起形成促進剤
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008324243B2 (en) 2007-11-05 2012-03-08 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
EP2404901B1 (en) 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (es) * 1969-06-30 1974-10-28
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (es) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
EP0002401B1 (fr) * 1977-11-24 1980-12-10 Synthelabo Dérivés de naphtalène, leur préparation et leur application en thérapeutique
US4886809A (en) * 1986-07-31 1989-12-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5656642A (en) * 1993-04-07 1997-08-12 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing piperidine derivative as active ingredient
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
DK0704439T3 (da) * 1993-06-18 2001-10-08 Fujisawa Pharmaceutical Co Hidtil ukendt mellemprodukt til syntetisk anvendelse og fremgangsmåde til fremstilling af aminopiperazinderivater
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
MX9707561A (es) * 1995-04-07 1997-12-31 Schering Corp Compuestos de carbonil piperazinilo y piperidinilo.
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
WO1997017957A1 (en) * 1995-11-13 1997-05-22 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
WO1998027930A2 (en) * 1996-12-24 1998-07-02 Fujisawa Pharmaceutical Co., Ltd. New use of aminopiperazine derivatives
JP2001511766A (ja) * 1997-02-17 2001-08-14 藤沢薬品工業株式会社 新規アミノピペラジン誘導体
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
CN1142910C (zh) 2004-03-24
BRPI0008753B8 (pt) 2021-05-25
US6710043B1 (en) 2004-03-23
IL143841A0 (en) 2002-04-21
KR100525809B1 (ko) 2005-11-03
CZ20012562A3 (cs) 2001-11-14
HU230422B1 (hu) 2016-05-30
KR20040063001A (ko) 2004-07-09
CN1336917A (zh) 2002-02-20
EP1140836A1 (en) 2001-10-10
ES2363492T3 (es) 2011-08-05
WO2000042011A1 (en) 2000-07-20
ZA200104713B (en) 2002-09-09
CA2360360A1 (en) 2000-07-20
RU2208608C2 (ru) 2003-07-20
JP3617454B2 (ja) 2005-02-02
EP1140836B1 (en) 2011-03-23
AUPP818099A0 (en) 1999-02-11
JP2004002414A (ja) 2004-01-08
HUP0105108A3 (en) 2002-11-28
KR20010093819A (ko) 2001-10-29
DE60045759D1 (de) 2011-05-05
CA2360360C (en) 2009-09-08
US20040014745A1 (en) 2004-01-22
BR0008753A (pt) 2001-11-06
HK1044337A1 (en) 2002-10-18
JP2002534503A (ja) 2002-10-15
HK1044337B (zh) 2004-11-26
KR100520406B1 (ko) 2005-10-11
ATE502923T1 (de) 2011-04-15
TR200102038T2 (tr) 2002-01-21
IL143841A (en) 2006-07-05
TWI229075B (en) 2005-03-11
BR0008753B1 (pt) 2013-11-12
HUP0105108A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
AR028812A1 (es) Compuestos de amida, utiles para potenciar la actividad colinergica; proceso para prepararlos; composiciones farmaceuticas formuladas con dichos compuestos; uso de dichos compuestos para preparar dichas composiciones y/o prevenir la amnesia y/o demencia y metodo para tratar dichas enfermedades
AR003005A1 (es) Compuestos derivados de benzamida, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, el metodo de tratamientoterapeutico y/o de prevencion con dichos compuestos, y las aplicaciones de dichos compuestos como medicamentos, y para la obtencion de medicamentos.
HUP9801887A2 (hu) CCR-3 receptor antagonista hatású gyűrűs aminszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
KR927003585A (ko) 헤테로사이클릭 화합물
AR038881A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos
ATE143355T1 (de) Pharmakologisch wirksame hydrazinderivate und verfahren zu deren herstellung
PT71940B (pt) Process for preparing morpholine derivatives
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
ES2082024T3 (es) Oximas y aminas azabiciclicas y azaciclicas utiles como agentes colinergicos y sus sales farmaceuticamente aceptables.
AR033996A1 (es) Una 7-oxo-piridopirimidina, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, un proceso para producir una pirimidina, un proceso para producir una piridopirimidina, y compuestos preparados mediante dichos procesos
UA27818C2 (uk) Похідні індолу, які мають властивості агоністів 5-от1d рецепторів, спосіб їх одержання, фармацевтична композиція
KR880001650A (ko) 트리아졸로피리딘 또는 트리아졸로퀴놀린의 신규 아미노알킬티오 유도체, 그의 제조방법 및 특히 진통제로서 유용한 그것이 존재하는 약제
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
DK492288A (da) Amidforbindelser, farmaceutisk praeparat indeholdende samme samt fremgangsmaade til fremstilling af forbindelserne
NO822693L (no) Fremgangsmaate ved fremstilling av terapeutisk aktive 1-fenyl-2-aminocarbonylindolforbindelser
BG105855A (en) 2-aminopyridines containing fused ring substituents
AR026222A1 (es) Compuestos derivados de acido antranilico
ES2021261A6 (es) Procedimiento de preparacion de nuevos derivados aminopropanoles racemicos u opticamente activos, sus sales de adicion acida y sus derivados amonicos cuaternarios.
YU46941B (sh) Aruloksi-ariltio-, heteroariloksi-, heteroariltio- alkenilenski derivati amina i postupak za njihovo dobijanje
IL73696A (en) N-(benzazepin-3-yl)-and n-(benzodiazepin-3-yl)-alkylene-n-indol-3-yl-alkylene-amine derivatives,their preparation and pharmaceutical compositions containing them
NZ217276A (en) Bicyclic heterocyclic compounds and pharmaceutical compositions
JP4644655B2 (ja) Lfa阻害剤として有用なジアゼパン誘導体
US2519408A (en) Antispasmodics
TH1363EX (th) สารประกอบเฮเทอโรไซคริค

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee